Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J

Ji Zhou1, Geoff H Werstuck, Sárka Lhoták

  • 1Department of Medicine, McMaster University, Hamilton, Ontario, Canada.

Insights

Hyperhomocysteinemia (HHcy) does not independently cause atherosclerosis in mice. However, HHcy can accelerate atherosclerotic lesion development when combined with diets that increase VLDL levels or inflammation.

Area of Science:

  • Cardiovascular Research
  • Nutritional Science
  • Metabolic Disease

Background:

  • Diet-induced hyperhomocysteinemia (HHcy) is linked to atherosclerosis in apoE(-/-) mice.
  • The independent role of HHcy in atherosclerosis, separate from hyperlipidemia and apoE deficiency, remains unclear.

Purpose of the Study:

  • To investigate if HHcy is an independent risk factor for accelerated atherosclerosis in C57BL/6J mice.
  • To determine if HHcy's proatherogenic effect depends on hyperlipidemia or inflammation.

Main Methods:

  • C57BL/6J mice were fed 6 different diets (chow, chow+methionine, western, western+methionine, atherogenic, atherogenic+methionine) for up to 40 weeks.
  • Plasma homocysteine, cysteine, glutathione, cholesterol, and triglycerides were analyzed.
  • Aortic root sections were examined for atherosclerotic lesions, macrophage foam cells, lymphocytes, hyaluronan, and ER stress markers.

Main Results:

  • Methionine supplementation induced HHcy in all relevant groups.
  • Atherosclerotic lesions were observed only in mice fed the atherogenic (A) or A+methionine (A+M) diets.
  • Lesion size was significantly larger in the A+M group compared to the A group at 10 and 20 weeks.
  • HHcy did not accelerate atherosclerosis with the western diet, which increased total plasma lipids.

Conclusions:

  • HHcy is not an independent cause of atherosclerosis in C57BL/6J mice, even with hyperlipidemia.
  • HHcy accelerates atherosclerotic lesion development under specific dietary conditions that promote VLDL elevation and/or inflammation.

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...